Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 3/20 | 0.59 |
| ▸ | PRKCZ known ✓ | Q05513 | 3/20 | 0.59 |
| ▸ | PRKCD known ✓ | Q05655 | 3/20 | 0.59 |
| ▸ | ROCK1 known ✓ | Q13464 | 3/20 | 0.59 |
| ▸ | JAK2 known ✓ | O60674 | 2/20 | 0.59 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.59 |
| ▸ | PRKCG known ✓ | P05129 | 2/20 | 0.39 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.39 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.59 |
| ▸ | CDK1 | P06493 | 3/20 | 0.59 |
| ▸ | PIM1 | P11309 | 3/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.59 |
| ▸ | CDK2 | P24941 | 3/20 | 0.59 |
| ▸ | AKT1 | P31749 | 3/20 | 0.59 |
| ▸ | AKT2 | P31751 | 3/20 | 0.59 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.59 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326351 | 0.99 | CHEK1 (0.60) | CHEK1DAPK3ROCK2CHEK2CDK1 | |
| Hydrochloric Acid SCHEMBL5973967 | 0.98 | CHEK1 (0.59) | CHEK1DAPK3ROCK2CHEK2CDK1 | |
| Hydrochloric Acid SCHEMBL5974249 | 0.96 | CHEK1 (0.58) | CHEK1DAPK3ROCK2CHEK2CDK1 | |
| Hydrochloric Acid SCHEMBL2274914 | 0.96 | CHEK1 (0.58) | CHEK1DAPK3ROCK2CHEK2CDK1 | |
| Hydrochloric Acid SCHEMBL5974369 | 0.96 | CHEK1 (0.58) | CHEK1DAPK3ROCK2CHEK2CDK1 | |
| Hydrochloric Acid SCHEMBL5974644 | 0.96 | CHEK1 (0.58) | CHEK1DAPK3ROCK2CHEK2CDK1 | |
| Hydrochloric Acid SCHEMBL5975382 | 0.96 | CHEK1 (0.58) | CHEK1DAPK3ROCK2CHEK2CDK1 | |
| SCHEMBL6329737 | 0.96 | CHEK1 (0.60) | CHEK1DAPK3ROCK2CHEK2CDK1 | |
| SCHEMBL6334525 | 0.95 | CHEK1 (0.59) | CHEK1DAPK3ROCK2CHEK2CDK1 | |
| SCHEMBL2954348 | 0.95 | CHEK1 (0.59) | CHEK1DAPK3ROCK2CHEK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1160240-B1 | Guanylhydrazones for treating inflammatory conditions | CYTOKINE PHARMASCIENCES INC (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-0746312-B1 | GUANYLHYDRAZONES FOR TREATING INFLAMMATORY CONDITIONS | PICOWER INST MED RES (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020028851-A1 | Aromatic guanylhydrazones (amidinohydrazones) used to prevent and ameliorating cachexia; to inhibit the uptake of arginine by macrophages and/or its conversion to urea; to prevent the generation of nitric oxide (NO) and tumor necrosis factor | BIANCHI MARINA (IT) | 2002-03-07 | — | — | US | disclosed |
| EP-1160240-A1 | Guanylhydrazones for treating inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6248787-B1 | REDUCING CACHEXIA | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2001-06-19 | — | — | US | disclosed |
| US-6180676-B1 | THERAPY FOR CACHEXIA | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH | 2001-01-30 | — | — | US | disclosed |
| US-6022900-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 2000-02-08 | — | — | US | disclosed |
| US-6008255-A | TREATING ENDOTOXIC SHOCK BY ADMINISTERING COMPOUNDS OF GIVEN FORMULA WHICH ARE AROMATICS SUBSTITUTED WITH MULTIPLE GUANYLHYDRAZONE MOIETIES, MORE PROPERLY TERMED AMIDINOHYDRAZONES (H2N-C(=NH)-NH-N=) | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1999-12-28 | — | — | US | disclosed |
| US-5859062-A | ADMINISTERING TO TREAT INFLAMMATORY DISEASES MEDIATED BY TUMOR NECROSIS FACTOR | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1999-01-12 | — | — | US | disclosed |
| US-5849794-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-12-15 | — | — | US | disclosed |
| US-5753684-A | Guanylhydrazones and their use to treat inflammatory conditions | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-05-19 | — | — | US | disclosed |
| US-5750573-A | PREVENTING AND TREATING CACHEXIA, THE CLINICAL SYNDROME OF POOR NUTRITION AND BODILY WASTING ASSOCIATED WITH CANCER AND CHRONIC DISEASES; ARGINASE INHIBITORS | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1998-05-12 | — | — | US | disclosed |
| US-5599984-A | AROMATIC AMIDINOHYDRAZONES AS INHIBITORS FOR THE UPTAKE OF ARGININE BY MACROPHAGES AND/OR ITS CONVERSION TO UREA; PREVENTION OF NITRIC OXIDE GENERATION; CACHEXIA; METABOLIC SYNDROMES | THE PICOWER INSTITUTE FOR MEDICAL RESEARCH (US) | 1997-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028851-A1 | Aromatic guanylhydrazones (amidinohydrazones) used to prevent and ameliorating cachexia; to inhibit the uptake of arginine by macrophages and/or its conversion to urea; to prevent the generation of nitric oxide (NO) and tumor necrosis factor | ARG1, ARG2, NOS3 | ROCK2 2405/4885PRKCZ 3831/4885PRKCD 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.